Literature DB >> 10643148

Hemolytic crisis after excessive ingestion of fava beans in a male infant with G6PD Canton.

A Shibuya1, A Hirono, S Ishii, H Fujii, S Miwa.   

Abstract

After ingesting fava beans, a 26-month-old Chinese-Japanese male infant showed a sickly complexion and yellowish-brownish skin and was hospitalized. Severe hemolytic anemia was observed on admission, and transfusion of 200 ml of packed red cells was required. Red cell enzyme assay revealed that the patient and the mother were deficient in glucose-6-phosphate dehydrogenase (G6PD). Subsequent molecular analysis showed that the patient had a missense mutation 1376 G to T (G6PD Canton) and his mother was a homozygote for the mutation. The patient was a son of a Chinese (Taiwanese) mother and a Japanese father. Although G6PD deficiency is rare in the original Japanese population, the number of "imported" cases could be rising rapidly. This is the first reported Japanese case of G6PD deficiency with G6PD Canton.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10643148

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  3 in total

1.  PharmGKB summary: very important pharmacogene information for G6PD.

Authors:  Ellen M McDonagh; Caroline F Thorn; José M Bautista; Ilan Youngster; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

2.  Glucose-6-phosphate dehydrogenase variants associated with favism in Thai children.

Authors:  Vichai Laosombat; Benjamas Sattayasevana; Teerachit Chotsampancharoen; Malai Wongchanchailert
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

3.  Genotypic and phenotypic landscapes of 51 pharmacogenes derived from whole-genome sequencing in a Thai population.

Authors:  Natnicha Wankaew; Pajaree Chariyavilaskul; Monpat Chamnanphon; Adjima Assawapitaksakul; Wanna Chetruengchai; Monnat Pongpanich; Vorasuk Shotelersuk
Journal:  PLoS One       Date:  2022-02-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.